Abstract
Sickle cell disease (SCD) is a potentially devastating and life threatening condition that is caused by an autosomal recessive inherited hemoglobinopathy which results in vaso-occlusive phenomena and hemolysis. The severity of this disorder is widely variable, but overall mortality is increased and life expectancy decreased when compared to the general population.
Care of patients with sickle cell disease is largely supportive. In fact, hydroxyurea is the only drug used that modifies disease pathogenesis. Painful vaso-occlusive events are the most common complication experienced by both children and adults with sickle cell disease and hydroxyurea is the only treatment option available to prevent the development of these events. Most events are managed with traditional supportive care measures (i.e. aggressive hydration, antiinflammatory and narcotic analgesics) that have not changed in decades. As such, there is an overwhelming need for both the development of new agents and new approaches to treatment with existing modalities for patients with sickle cell disease.
Keywords: Sickle cell disease, therapeutics, treatment, children.
Current Pharmaceutical Design
Title:Pharmacotherapy of Sickle Cell Disease in Children
Volume: 21 Issue: 39
Author(s): Kathleen A. Neville and Julie A. Panepinto
Affiliation:
Keywords: Sickle cell disease, therapeutics, treatment, children.
Abstract: Sickle cell disease (SCD) is a potentially devastating and life threatening condition that is caused by an autosomal recessive inherited hemoglobinopathy which results in vaso-occlusive phenomena and hemolysis. The severity of this disorder is widely variable, but overall mortality is increased and life expectancy decreased when compared to the general population.
Care of patients with sickle cell disease is largely supportive. In fact, hydroxyurea is the only drug used that modifies disease pathogenesis. Painful vaso-occlusive events are the most common complication experienced by both children and adults with sickle cell disease and hydroxyurea is the only treatment option available to prevent the development of these events. Most events are managed with traditional supportive care measures (i.e. aggressive hydration, antiinflammatory and narcotic analgesics) that have not changed in decades. As such, there is an overwhelming need for both the development of new agents and new approaches to treatment with existing modalities for patients with sickle cell disease.
Export Options
About this article
Cite this article as:
A. Neville Kathleen and A. Panepinto Julie, Pharmacotherapy of Sickle Cell Disease in Children, Current Pharmaceutical Design 2015; 21 (39) . https://dx.doi.org/10.2174/1381612821666151030105213
DOI https://dx.doi.org/10.2174/1381612821666151030105213 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer
Reviews on Recent Clinical Trials Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews Recent Developments in Cardiovascular Drug Therapy: Treatment of Atrial Arrhythmias with New Class III Drugs and beyond
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The NPC1L1 Inhibitor Ezetimibe in the Treatment of the Dyslipidemia in Patients Affected by the Metabolic Syndrome: Evidences and Perspectives
Current Enzyme Inhibition Coarctation of the Aorta - An Evolution of Therapeutic Options
Current Cardiology Reviews EDITORIAL (Thematic Issue: Preeclampsia and Modern Approaches to Diagnosis and Therapy)
Current Women`s Health Reviews Gene Modified Cell Transplantation for Vascular Regeneration
Current Gene Therapy Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters Mexiletine Metabolites: A Review
Current Medicinal Chemistry Improving Patient Compliance with Hypertension Treatment: Mission Possible?
Current Vascular Pharmacology Percutaneous Pulmonary Valve Implantation: Current Status and Future Perspectives
Current Cardiology Reviews The Application of NMR Spectroscopy for the Study of Heart Failure
Current Pharmaceutical Design Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Pulmonary Valve Endocarditis: A Case Report
Infectious Disorders - Drug Targets